Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hematologic problems in systemic lupus erythematosus]

T Robak1, E Robak, A Sysa-Jedrzejowska

  • 1II Kliniki Chorób Wewnetrznych AM w Lodzi.

Acta Haematologica Polonica
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.

ESMO open·2022
Same author

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial).

Leukemia·2017
Same author

appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies).

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia.

Blood cancer journal·2015
Same journal

[Risk of transmission of blood-derived pathogens by transfusion in Poland].

Acta haematologica Polonica·2020
Same journal

[Emerging infectious diseases in the context of blood safety].

Acta haematologica Polonica·2020
Same journal

<i>Quo Vadis</i> medycyno regeneracyjna?: Quo Vadis Regenerative Medicine?

Acta haematologica Polonica·2013
Same journal

[RHnull syndrome--diagnostic and therapeutic problems].

Acta haematologica Polonica·1996
Same journal

[Unclassified chronic myeloproliferative Ph(-); i(17q); +8 syndrome with mixed myelo-megakaryoblastic crisis--case report].

Acta haematologica Polonica·1996
Same journal

Acute myelofibrosis in children: report on two cases.

Acta haematologica Polonica·1996
See all related articles

Systemic lupus erythematosus (SLE) significantly impacts immune function, frequently causing anemia, leucopenia, and thrombocytopenia. These hematological changes necessitate vigilant monitoring and timely treatment in SLE patients.

Area of Science:

  • Immunology
  • Hematology

Context:

  • Systemic lupus erythematosus (SLE) is an autoimmune disease with unknown etiology.
  • SLE involves significant dysregulation of both cellular and humoral immunity.
  • Hematological abnormalities are prevalent in over half of SLE patients.

Purpose:

  • To review the common hematological changes observed in Systemic Lupus Erythematosus.
  • To discuss the potential causes and implications of anemia, leucopenia, and thrombocytopenia in SLE.
  • To emphasize the importance of monitoring and managing these hematological issues.

Summary:

  • Anemia, leucopenia, and thrombocytopenia are common hematological findings in SLE.
  • Anemia in SLE can stem from chronic disease, autoimmune hemolysis, or hypoplasia.

Related Experiment Videos

  • Leucopenia may result from autoantibodies, drug effects, hypersplenism, or marrow suppression.
  • Thrombocytopenia in SLE is typically autoimmune and associated with an increased risk of thrombosis.

    • Impact:

    • Highlights the critical role of hematological monitoring in SLE patient care.
    • Underscores the need for prompt therapeutic interventions for hematological abnormalities in SLE.
    • Informs clinicians about the diverse causes and potential complications of blood count disturbances in SLE.